Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent

Journal of Pharmaceutical Sciences

Volumn 94, Issue 4, 2005, Pages 828-836

  Hammell, Dana C ^a   Stolarczyk, Elzbieta I ^a   Klausner, Mitch ^b   Hamad, Mohamed O ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

^b MATTEK CORPORATION   (United States)

Author keywords

EpiDerm ; in vitro models; Naltrexone; Percutaneous absorption; Prodrugs; Tissue engineering; Transdermal drug delivery

Indexed keywords

ALKYL GROUP; ESTER DERIVATIVE; NALTREXOL; NALTREXONE; NALTREXONE 3 O (2' ETHYL BUTYRATE); NALTREXONE 3 O VALERATE; NALTREXONE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; DRUG DIFFUSION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; HYDROLYSIS; IN VITRO STUDY; QUANTITATIVE ANALYSIS; SKIN ABSORPTION;

EID: 17744396161     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20238     Document Type: Article

References (14)

1. Carreno JE, Alvarez CE, San Narciso GI, Bascaran MT, Diaz M, Bobes J. 2003. Maintenance treatment with depot opioid antagonists in subcutaneous implants: An alternative in the treatment of opioid dependence. Addict Biol 8:429-438.
2. Volpicelli JR, Rhines KC, Rhines JS. 1997. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54:737-743.
3. Litten R, Allen J. 1998. Advances in the development of medications for alcoholism. Psychopharmacology (Berl) 139:20-33.
4. Stinchcomb AL, Swaan PW, Ekabo O, Harris KK, Browe J, Hammell DC, Cooperman TA, Pearsall M. 2002. Straight-chain naltrexone ester prodrugs: Diffusion and concurrent esterase biotransformation in human skin. J Pharm Sci 91:2571-2578.
5. Stinchcomb AL. 2003. Xenobiotic bioconversion in human epidermis models. Pharm Res 20:1113-1118.
6. McCaul ME, Wand GS, Rohde C, Lee SM. 2000. Serum 6β-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res 24:1385-1391.
7. Rukstalis MR, Stromberg MF, O'Brien CP, Volpicelli JR. 2000. 6-Beta-naltrexol reduces alcohol consumption in rats. Alcohol Clin Exp Res 24: 1593-1596.
8. Porter SJ, Somogyi AA, White JM. 2000. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 50:465-471.
9. Wang D, Raehal KM, Bilsky EJ, Sadee W. 2001. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): Possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600.
10. Lamb KA, Denyer SP, Sanderson FD, Shaw PN. 1994. The metabolism of a series of ester pro-drugs by NCTC 2544 cells, skin homogenate and LDE testskin. J Pharm Pharmacol 46:965-973.
11. Hussain MA, Koval CA, Myers MJ, Shami EG, Shefter E. 1987. Improvement of the oral bioavailability of naltrexone in dogs: A prodrug approach. J Pharm Sci 76:356-358.
12. Pillai O, Hamad MO, Crooks PA, Stinchcomb AL. 2004. Physicochemical evaluation, in vitro human skin diffusion and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharmaceut Res 21:1146-1152.
13. Bickers DR, Mukhtar H. 1991. Dermal metabolism of drugs and carcinogens. In: Scott RC, editor. Predict. Percutaneous Penetration. London: IBC Tech Serv., pp 248-258.
14. Xiang TX, Anderson BA. 1998. Influence of chain ordering on the selectivity of dipalmitoylphosphatidylcholine bilayer membranes for permeant size and shape. Biophys J 75:2658-2671.